Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $37.40 | Total: $187.00 |
| 1 | 10 | $31.68 | Total: $316.80 |
| 1 | 25 | $26.84 | Total: $671.00 |
| 1 | 50 | $22.88 | Total: $1,144.00 |
| 1 | 100 | $19.80 | Total: $1,980.00 |
Overview
CAY10746 is a selective Rho kinase (ROCK) inhibitor, targeting ROCK I and ROCK II with IC50 values of 0.014 ?M and 0.003 ?M, respectively. CAY10746 can be employed in the study of diabetic retinopathy.
Chemical Properties
| Molecular Formula | C26H23N3O5 |
| Molecular Weight | 457.48 |
| CAS Numbers | 2247240-76-0 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CN(C)c1ccc(cc1)C(=O)Nc1cccc(NC(=O)COc2ccc3c(c2)occc3=O)c1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Zhao L, et al. Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase [ROCK] Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models. J Med Chem. 2019 Dec 12;62[23] 10691-10710.